BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no serious adverse events HAYWARD, Calif. --(BUSINESS WIRE)--Nov. 6, 2026-- Pulse Biosciences, Inc.

Related news

PLSEPulse Biosciences2026-09-15 11:00 EST

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

PLSEPulse Biosciences2026-10-14 11:00 EST

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

ICUSeaStar Medical2026-11-03 13:21 EST

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

JNJJohnson & Johnson2026-10-23 17:42 EST

Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractaire

IARTIntegra LifeSciences2026-10-16 12:40 EST

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

IRIXIRIDEX2026-10-12 11:00 EST

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-11-06 12:00 EST

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

PLSEPulse Biosciences2026-11-05 21:05 EST

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

PLSEPulse Biosciences2026-10-29 17:05 EST

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

PLSEPulse Biosciences2026-10-14 11:00 EST

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Stock data

Close
53.07 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States